A decision aid for considering indomethacin prophylaxis vs. symptomatic treatment of PDA for extreme low birth weight infants

BMC Pediatrics

Saleh A Al-Alaiyan²  Turki M AlKharfi¹  Eman Al Luwaimi¹  Khalid M AlFaleh¹ 

[1] Department of Pediatrics (Division of Neonatology), College of Medicine, King Saud University, Riyadh, Saudi Arabia;Department of Pediatrics (Division of Neonatology), King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

关键词: premature infants;    intraventricular hemorrhage;    patent ductus arteriosus;    Indomethacin;   

Others  :  1172131
DOI  :  10.1186/1471-2431-11-78

 received in 2010-09-28, accepted in 2011-09-03,  发布年份 2011

【 摘 要 】

Background

Decision Aids (DA) are well established in various fields of medicine. It can improve the quality of decision-making and reduce decisional conflict. In neonatal care, and due to scientific equipoise, neonatologists caring for extreme low birth weight (ELBW) infants are in need to elicit parents' preferences with regard to the use of indomethacin therapy in ELBW infants. We aimed to develop a DA that elicits parents' preferences with regard to indomethacin therapy in ELBW infants.

Methods

We developed a DA for the use of the indomethacin therapy in ELBW infants according to the Ottawa Decision Support Framework. The development process involved parents, neonatologists, DA developers and decision making experts. A pilot testing with healthy volunteers was conducted through an evaluation questionnaire, a knowledge scale, and a validated decisional conflict scale.

Results

The DA is a computer-based interactive tool. In the first part, the DA provides information about patent ductus arteriosus (PDA) as a disease, the different treatment options, and the benefits and downsides of using indomethacin therapy in preterm infants. In the second part, it coaches the parent in the decision making process through clarifying values and preferences. Volunteers rated 10 out of 13 items of the DA positively and showed significant improvement on both the knowledge scale (p = 0.008) and the decisional conflict scale (p = 0.008).

Conclusion

We have developed a computer based DA to assess parental preferences with regard to indomethacin therapy in preterm infants. Future research will involve measurement of parental preferences to guide and augment the clinical decisions in current neonatal practice.

【 授权许可】

   
2011 AlFaleh et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]St John EB, Carlo WA: Respiratory distress syndrome in VLBW infants: changes in management and outcomes observed by the NICHD Neonatal Research Network. Semin Perinatol 2003, 27:288-292.
• [2]Wyllie J: Treatment of patent ductus arteriosus. Semin Neonatol 2003, 8:425-432.
• [3]Laughon MM, Simmons MA, Bose CL: Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr 2004, 16:146-151.
• [4]Marshall DD, Kotelchuck M, Young TE, Bose CL, Kruyer L, O'Shea TM: Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. North Carolina Neonatologists Association. Pediatrics 1999, 104:1345-1350.
• [5]Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G: Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995, 126:605-610.
• [6]Shimada S, Kasai T, Hoshi A, Murata A, Chida S: Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. Pediatr Int 2003, 45:255-262.
• [7]Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clarke RH: Necrotizing enterocolitis among neonates in the United States. J Perinatol 2003, 23:278-285.
• [8]Osborn DA, Evans N, Kluckow M: Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant. Arch Dis Child Fetal Neonatal Ed 2003, 88:F477-F482.
• [9]Kluckow M, Evans N: Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage. J Pediatr 2000, 137:68-72.
• [10]Lewis MJ, McKeever PK, Rutty GN: Patent ductus arteriosus as a natural cause of pulmonary hemorrhage in infants: a medico legal dilemma. Am J Forensic Med Pathol 2004, 25:200-204.
• [11]Fowlie PW, Davis PG: Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 2003, 88:F464-F466.
• [12]Fowlie PW, Davis PG: Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2002, CD000174.
• [13]Alfaleh K, Smyth JA, Roberts RS, Solimano A, Asztalos EV, Schmidt B: Trial of Indomethacin Prophylaxis in Preterms Investigators, Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. Pediatrics 2008, 121(2):e233.
• [14]Clyman RI, Saha S, Jobe A, Oh W: Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr 2007, 150(1):46-50. e2
• [15]O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Changura S, Llwelline-Thomas H, Rovner D: Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews 2009, (3):Art. No CD001431.
• [16]Kennedy A, Sculpher MJ, Coulter A, Dwyer N, Rees M, Abrams KR, Horsley S, Cowley D, Kidson C, Kirwin C, Naish C, Stirrat G: Effects of Decision Aids for Menorrhagia on Treatment Choices, Health Outcomes, and Costs A Randomized Controlled Trial. JAMA 2002, 288(21):2701-2708.
• [17]Metcalfe KA, Poll A, O'Connor A, Gershman S, Armel S, Finch A, Demsky R, Rosen B, Narood SA: Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet 2007, 72(3):208-17.
• [18]O'Connor AM: Validation of a decisional conflict scale. Medical Decision Making 1995, 15(1):25-30.